New research discovers a new combination of therapy for people with a type of leukemia, leading them to live longer

In a new multicenter international study led by the Mayo Clinic Comprehensive Cancer Center, researchers found that people with the B-cell precursor subtype of acute lymphoblastic leukemia (BCP-ALL), who also lacked a genetic abnormality known as the Philadelphia chromosome and were in remission with no trace of cancer, showed significantly higher survival rates when blinatumomab was added to their chemotherapy treatment.